Background: Despite sensitivity to first-line chemotherapy, most small-cell lung cancer (SCLC) patients relapse. In this setting, topotecan demonstrated modest activity with significant toxicity. Paclitaxel was also active. This study was designed to evaluate activity and safety of nab-paclitaxel in relapsed SCLC. Methods: In this multicentre prospective Phase 2 trial, patients with refractory or sensitive SCLC progressed to first-line platinum-based chemotherapy received nab-paclitaxel 100 mg/smq on days 1, 8, 15 every 4 weeks up to six cycles, progressive disease or intolerable toxicity. Primary endpoint was investigator-assessed objective tumour response. Secondary endpoints were toxicity, progression-free survival (PFS) and overall survival (OS). Results: Of the 68 patients treated, partial response was 8% in the refractory cohort and 14% in the sensitive cohort. Most common toxicities of any grade were fatigue (54%), anaemia (38%), neutropenia (29%), leukopenia (26%) and diarrhoea (21%). Median PFS was similar in both refractory (1.8 months) and sensitive cohorts (1.9 months), while median OS was longer in sensitive one (6.6 versus 3.6 months). Conclusions: Although nab-paclitaxel has shown some modest anti-tumour activity in relapsed SCLC, associated with a favourable toxicity profile, the primary end-point of the study was not met. Clinical Trial registration: Clinical Trial registration number is ClinicalTrials.gov Identifier: NCT03219762.

Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) / Gelsomino, F.; Tiseo, M.; Barbieri, F.; Riccardi, F.; Cavanna, L.; Frassoldati, A.; Delmonte, A.; Longo, L.; Dazzi, C.; Cinieri, S.; Colantonio, I.; Sperandi, F.; Lamberti, G.; Brocchi, S.; Tofani, L.; Boni, L.; Ardizzoni, A.. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - 123:1(2020), pp. 26-32. [10.1038/s41416-020-0845-3]

Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)

Tiseo M.;
2020-01-01

Abstract

Background: Despite sensitivity to first-line chemotherapy, most small-cell lung cancer (SCLC) patients relapse. In this setting, topotecan demonstrated modest activity with significant toxicity. Paclitaxel was also active. This study was designed to evaluate activity and safety of nab-paclitaxel in relapsed SCLC. Methods: In this multicentre prospective Phase 2 trial, patients with refractory or sensitive SCLC progressed to first-line platinum-based chemotherapy received nab-paclitaxel 100 mg/smq on days 1, 8, 15 every 4 weeks up to six cycles, progressive disease or intolerable toxicity. Primary endpoint was investigator-assessed objective tumour response. Secondary endpoints were toxicity, progression-free survival (PFS) and overall survival (OS). Results: Of the 68 patients treated, partial response was 8% in the refractory cohort and 14% in the sensitive cohort. Most common toxicities of any grade were fatigue (54%), anaemia (38%), neutropenia (29%), leukopenia (26%) and diarrhoea (21%). Median PFS was similar in both refractory (1.8 months) and sensitive cohorts (1.9 months), while median OS was longer in sensitive one (6.6 versus 3.6 months). Conclusions: Although nab-paclitaxel has shown some modest anti-tumour activity in relapsed SCLC, associated with a favourable toxicity profile, the primary end-point of the study was not met. Clinical Trial registration: Clinical Trial registration number is ClinicalTrials.gov Identifier: NCT03219762.
2020
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) / Gelsomino, F.; Tiseo, M.; Barbieri, F.; Riccardi, F.; Cavanna, L.; Frassoldati, A.; Delmonte, A.; Longo, L.; Dazzi, C.; Cinieri, S.; Colantonio, I.; Sperandi, F.; Lamberti, G.; Brocchi, S.; Tofani, L.; Boni, L.; Ardizzoni, A.. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - 123:1(2020), pp. 26-32. [10.1038/s41416-020-0845-3]
File in questo prodotto:
File Dimensione Formato  
NABSTER_Br J Cancer_revised paper[FG].pdf

Open Access dal 30/04/2020

Descrizione: Articolo principale
Tipologia: Documento in Post-print
Licenza: Creative commons
Dimensione 193.95 kB
Formato Adobe PDF
193.95 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2881516
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 15
social impact